Latest news with #IntegratedDNATechnologies
Yahoo
16-06-2025
- Business
- Yahoo
Integrated DNA Technologies Announces Innovation Roadmap Advances to Infectious Disease Portfolio
Expanded portfolio offerings include first-to-market product launches to support global health challenges New infectious disease research solutions to be spotlighted at ASM Microbe 2025 CORALVILLE, Iowa, June 16, 2025--(BUSINESS WIRE)--Integrated DNA Technologies (IDT), a global genomics leader, is expanding its infectious disease portfolio with new solutions to enhance worldwide research efforts in monitoring infectious disease dynamics, supporting surveillance and accelerating biomarker discovery. As part of its innovation roadmap, focused on enabling academic and medical researchers, health organizations, and the scientific community prepare for ongoing and future global health challenges, IDT has unveiled two new powerful tools: The PrimeTime™ Influenza Kit and PrimeTime Research Pathogen Panels. These differentiated offerings expand upon IDT's current infectious disease portfolio of qPCR and next generation sequencing (NGS) solutions comprised of stand-alone library preparation, target enrichment and normalization chemistries, as well as connected DNA solutions, to support researchers exploring viral evolution, epidemiological studies, drug resistance mechanisms, drug development research and more. First to Market: Complete Solution for Influenza Research Launching at ASM Microbe 2025 is IDT's PrimeTime Influenza Kit, the first complete qPCR solution of its kind designed specifically to amplify common influenza strains. The kit targets Influenza A, Influenza A (H5N1), Influenza B, and RNase. It includes an internal control for sample quality assessment, a pre-mixed primer and probe set, PrimeTime 4x Broad-Range Master Mix and direct amplification enhancer. This streamlined solution enables researchers to generate high-confidence data for both seasonal and emerging influenza strains. New Cost-effective Solution to Accelerate Sexual Health and Pathogen Research IDT is also showcasing its new PrimeTime Research Pathogen Panels, a customizable, high-throughput solution that allows researchers to identify key sequences and mutations across 10 diverse research applications—spanning respiratory, gastrointestinal and sexual health studies—and an 11th category for viral infection research. The mix-and-match format across targets and dyes enables scientists to select from a broad list of targets to maximize cost and time savings. The panels' flexible assay configuration facilitates rapid, multiplexed detection and characterization of pathogens, with up to 211 available targets including sexually transmitted infections, human papillomavirus, urinary tract infections and more. With seamless integration into existing qPCR workflows, this single-tube offering equips researchers with innovative tools for exploring pathogen dynamics across individual and population-level studies. "Building on IDT's storied impact on the global fight against infectious diseases, these new tools reflect the ongoing innovation investments we're making to empower researchers to stay ahead of current and emerging health challenges," said Adler Edward, VP, Gene Reading Components at IDT. "By delivering robust, customizable and high-quality solutions, backed by IDT's trusted technical and scientific expertise, researchers can feel confident in accelerating their discoveries and deepening their understanding of pathogen dynamics in human health." To learn more about IDT's infectious disease innovation roadmap and how these new offerings are shaping the future of virus transmission research, visit IDT at ASM Microbe 2025 at booth #1723. To place an order, click here. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations. View source version on Contacts Media Contacts:Integrated DNA Technologies idtpr@ 800-328-2661 (USA & Canada)+1 319-626-8400 (outside USA) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
16-06-2025
- Health
- Business Wire
Integrated DNA Technologies Announces Innovation Roadmap Advances to Infectious Disease Portfolio
CORALVILLE, Iowa--(BUSINESS WIRE)-- Integrated DNA Technologies (IDT), a global genomics leader, is expanding its infectious disease portfolio with new solutions to enhance worldwide research efforts in monitoring infectious disease dynamics, supporting surveillance and accelerating biomarker discovery. As part of its innovation roadmap, focused on enabling academic and medical researchers, health organizations, and the scientific community prepare for ongoing and future global health challenges, IDT has unveiled two new powerful tools: The PrimeTime™ Influenza Kit and PrimeTime Research Pathogen Panels. These differentiated offerings expand upon IDT's current infectious disease portfolio of qPCR and next generation sequencing (NGS) solutions comprised of stand-alone library preparation, target enrichment and normalization chemistries, as well as connected DNA solutions, to support researchers exploring viral evolution, epidemiological studies, drug resistance mechanisms, drug development research and more. 'Building on IDT's storied impact on the global fight against infectious diseases, these new tools reflect the ongoing innovation investments we're making to empower researchers to stay ahead of current and emerging health challenges,' said Adler Edward. Share First to Market: Complete Solution for Influenza Research Launching at ASM Microbe 2025 is IDT's PrimeTime Influenza Kit, the first complete qPCR solution of its kind designed specifically to amplify common influenza strains. The kit targets Influenza A, Influenza A (H5N1), Influenza B, and RNase. It includes an internal control for sample quality assessment, a pre-mixed primer and probe set, PrimeTime 4x Broad-Range Master Mix and direct amplification enhancer. This streamlined solution enables researchers to generate high-confidence data for both seasonal and emerging influenza strains. New Cost-effective Solution to Accelerate Sexual Health and Pathogen Research IDT is also showcasing its new PrimeTime Research Pathogen Panels, a customizable, high-throughput solution that allows researchers to identify key sequences and mutations across 10 diverse research applications—spanning respiratory, gastrointestinal and sexual health studies—and an 11th category for viral infection research. The mix-and-match format across targets and dyes enables scientists to select from a broad list of targets to maximize cost and time savings. The panels' flexible assay configuration facilitates rapid, multiplexed detection and characterization of pathogens, with up to 211 available targets including sexually transmitted infections, human papillomavirus, urinary tract infections and more. With seamless integration into existing qPCR workflows, this single-tube offering equips researchers with innovative tools for exploring pathogen dynamics across individual and population-level studies. 'Building on IDT's storied impact on the global fight against infectious diseases, these new tools reflect the ongoing innovation investments we're making to empower researchers to stay ahead of current and emerging health challenges,' said Adler Edward, VP, Gene Reading Components at IDT. 'By delivering robust, customizable and high-quality solutions, backed by IDT's trusted technical and scientific expertise, researchers can feel confident in accelerating their discoveries and deepening their understanding of pathogen dynamics in human health.' To learn more about IDT's infectious disease innovation roadmap and how these new offerings are shaping the future of virus transmission research, visit IDT at ASM Microbe 2025 at booth #1723. To place an order, click here. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
Business Wire
05-05-2025
- Business
- Business Wire
Integrated DNA Technologies Brings Innovation Nexus to San Francisco Bay Area
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Global genomics solutions leader Integrated DNA Technologies (IDT) is investing technological capabilities and resources to launch a new innovation hub and support the Bay Area biotech cluster. Located at IDT's Redwood City site, in lockstep with its research and development (R&D) facility, the innovation nexus will serve as a collaboration center that enables IDT to innovate with regional customers, forge strategic partnerships, and drive R&D initiatives with leading-edge biotechnology companies. 'The installation of IDT's Innovation Nexus reflects our commitment to engaging closely with customers and strategic partners, and equipping them with novel solutions, tools of unrivalled quality, and trusted expertise,' said Linda De Jesus. Share The establishment of the innovation nexus is a pivotal element of IDT's strategic roadmap, aimed at acquiring emerging and transformative synthesis technologies ranging from novel chemistries, enzymatic synthesis, and alternative platforms, and driving market growth in precision oncology through advanced next generation sequencing (NGS) applications. Today, the company's NGS portfolio is comprised of xGen™ offerings which include standalone library preparation, target enrichment and normalization chemistries, as well as IDT Archer connected NGS solutions with end-to-end assay platforms, including secondary analysis capabilities and seamless tertiary software integrations. These differentiated solutions have been indispensable to cancer researchers, who rely on strong cancer insights, including both high-quality sequencing and data interpretation. 'The installation of IDT's Innovation Nexus reflects our commitment to engaging closely with customers and strategic partners, and equipping them with novel solutions, tools of unrivalled quality, and trusted expertise,' said Linda De Jesus, VP/GM Global Head of Commercial at Integrated DNA Technologies. 'Building off of our strong foundation in oligo synthesis technologies, IDT today is more than oligos, and we're proud of the evolution we're making to continually innovate with customers, to bring them high-quality technical capabilities and deep scientific knowledge.' The IDT Innovation Nexus complements IDT's rich legacy of innovation, which stems from its origins in Coralville, Iowa. Today, the company's Coralville headquarters remain a center of innovation with its oligo synthesis capabilities, which the company continually optimizes for high-throughput approaches. The Redwood City-based Innovation Nexus also welcomes a new IDT leader with more than a decade of experience who will spearhead the transformation and adoption of new technologies to meet customer needs. The newly created position will oversee a team of scientific experts in transforming IDT's technical capabilities, with a dedicated focus on R&D efforts that will build upon IDT's legacy portfolio and proven expertise in oligo synthesis technologies. To learn how IDT's innovative genomic solutions and bespoke capabilities are accelerating the world's greatest scientific breakthroughs, click here. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
